At the start of November 2026, Europe does not appear to be entering a broad respiratory wave. The ECDC reported that, in week 44, respiratory disease activity in the EU/EEA remained at baseline or low levels. Of the viruses being monitored, SARS-CoV-2 was the principal contributor and was increasing in several countries. Influenza activity was still low, although the trend was rising in some countries, while RSV remained very low.
For more information about the ECDC, see also Influenza 2026–2027 in Romania: INSP case figures, symptoms, vaccination and the risk of complications, which provides additional context on the subject.
This distinction matters for those inclined to read the start of every cold season as “the start of flu season”. Europe’s current picture is different: SARS-CoV-2 is more visible in integrated surveillance, while overall respiratory disease levels are not, for now, high.
What is known now: the ECDC is not announcing a new Europe-wide COVID-19 wave. It describes respiratory activity that remains low, alongside increased SARS-CoV-2 circulation in several countries. Both can be true at the same time.
Why SARS-CoV-2 can be “ahead” during a quiet period
The term “principal contributor” in the ECDC bulletin should not automatically be read as meaning “the largest number of people ill in Europe”. It describes the virus’s contribution to integrated surveillance indicators, which combine data from healthcare networks, laboratories and, where available, severity indicators.
A virus can account for the most important share of detections or signals tracked by a system even when respiratory consultations and hospital admissions remain low. Likewise, an increase from a low baseline may be epidemiologically relevant for monitoring, but is not the same as substantial pressure on hospitals.
The ECDC’s ERVISS platform brings together surveillance of influenza, RSV and SARS-CoV-2 for the EU/EEA and the WHO European Region. Its advantage is that it allows signals from several viruses to be compared. Its limitation is that it does not automatically turn those signals into a census of every infection in the population.
Three figures not to confuse
Much of the confusion at the start of each season comes from using the same label — “cases” — for data that in fact answer different questions.
| Indicator | What it may show | What it cannot establish on its own |
|---|---|---|
| Reported respiratory infections | The overall volume of consultations or cases classified as respiratory conditions | Which specific virus is dominant |
| Positive tests / viral detections | Which agent is identified more often in the surveillance network | The true number of all people infected |
| Hospital admissions, ICU admissions, deaths | Severity and pressure on the health system | How many mild infections are circulating in the community |
This is why the ECDC’s statement about SARS-CoV-2 and a decline in an aggregated Romanian report are not contradictory. They come from systems that measure different things.
Romania: total respiratory infections fell, but the data do not show which virus is dominant
For the week of 26 October to 1 November 2026, figures attributed to Romania’s National Institute of Public Health (INSP) by AGERPRES indicate 68,284 respiratory infections, 13.5% fewer than in the previous week. The total was 0.2% above the level in the comparable week of the previous season.
Over the same period, 213 clinical influenza cases and six laboratory-confirmed influenza cases were reported; no new influenza-associated death was announced. A week earlier, for 19–25 October, the report recorded 78,876 respiratory infections, 225 clinical influenza cases and eight laboratory confirmations.
These figures show a week-on-week reduction in the reported total, not a demonstrated decline for every respiratory virus. In particular, the total includes categories of respiratory conditions and is not a national, virus-by-virus series comparable with the ECDC indicators for SARS-CoV-2, influenza and RSV.
No equivalent Romanian series was identified in public sources for the same period that would allow a conclusion as to whether SARS-CoV-2 is, or is not, the principal contributor in Romania as well. This is an important limitation of the comparison: Romania may be included in the European picture as a country under surveillance, but it cannot responsibly be described as an exact reflection of the European average on the basis of these aggregated data.
Why reported COVID-19 numbers no longer reflect actual circulation
Interpreting SARS-CoV-2 is more difficult than it was in the first years of the pandemic. WHO warns that reported COVID-19 figures no longer faithfully reflect the true infection rate: many countries have scaled back routine testing, changed their reporting or incorporated the virus into broader respiratory surveillance systems.
That does not make the available data useless. It does mean they should be read as surveillance signals, rather than a complete count of all infections. A small number of reported cases may mean low circulation, but it may also reflect reduced testing. For the same period, trends in consultations, test positivity and hospital admissions are more useful indicators when they are published together.
Influenza rises slowly while RSV remains very low in Europe
Influenza is not absent from the picture: the ECDC says activity remains low but is increasing in several countries. The accurate wording, therefore, is “still low”, not “non-existent”. An influenza season may intensify later, and the 6 November bulletin is a snapshot rather than a forecast for the months ahead.
RSV is very low in the current European assessment. Even so, low population-level activity does not remove the individual risk for infants, older people or people with chronic illnesses. For these groups, an episode of difficulty breathing, unusual drowsiness, dehydration or a rapid deterioration in general condition warrants medical assessment, regardless of the overall level of viral circulation.
What to watch before the peak period
Over the coming weeks, a clearer picture will not come from a single number. It would be more meaningful if several indicators moved in the same direction: consultations for acute respiratory infections, the share of tests positive for each virus, admissions for severe illness and death data.
- A rise in SARS-CoV-2 test positivity without rising hospital admissions may primarily signal more active viral circulation.
- A simultaneous increase in consultations, hospital admissions and influenza detections would suggest entry into a more intense seasonal phase.
- Local data should be compared with European data cautiously, as testing and reporting criteria may differ.
For prevention, the measures remain proportionate to the situation: staying home when symptoms develop and a person feels unwell, ventilating indoor spaces, hand hygiene and protecting vulnerable people. The influenza vaccine is intended for influenza; it does not protect against SARS-CoV-2 or RSV. On 27 October, Romania’s Ministry of Health announced the availability of 370,000 influenza vaccine doses and an estimated delivery of around 500,000 doses by mid-November.
For the differences between common seasonal infections and the role of exposure to cold, see InfoBuz’s explanation of why we catch colds more often in winter. Symptoms alone cannot establish which virus is responsible; testing and medical assessment are particularly useful when there is a risk of complications or severe illness.
Frequently asked questions
Do the ECDC data mean a new COVID-19 wave is starting in Europe?
No. For week 44 of 2026, the ECDC described respiratory activity at baseline or low levels and an increase in SARS-CoV-2 in several countries. It is a signal to monitor, not confirmation of a broad wave.
Is SARS-CoV-2 the dominant virus in Romania too?
This cannot be stated on the basis of the public data identified for the period examined. The available Romanian reporting provides an aggregated total for respiratory infections and influenza data, but no comparable series for SARS-CoV-2, influenza and RSV.
Why are there so few laboratory-confirmed influenza cases compared with total respiratory infections?
The total number of respiratory infections covers several diagnoses and infectious agents, while laboratory confirmations also depend on who is tested. The two figures do not measure the same thing.
Does the influenza vaccine protect against COVID-19 or RSV?
No. The influenza vaccine is designed to reduce the risk of influenza and its associated complications. Protection against SARS-CoV-2 and RSV is a separate matter.
Sources consulted
- ECDC — Weekly respiratory virus update, week 44, October 2026
- ECDC — The European Respiratory Virus Surveillance Summary (ERVISS)
- WHO — COVID-19 dashboard summary
- AGERPRES — INSP: more than 68,000 respiratory infection cases recorded in one week in Romania
- AGERPRES — INSP: 78,876 respiratory infection cases reported in the week of 19–25 October










Discuția cititorilor
Ai o opinie sau o întrebare despre acest articol? Spune-ne ce crezi.
Fii primul care deschide discuția.
Te rugăm să păstrezi un limbaj civilizat și să discuți la subiect. Comentariile spam sunt filtrate automat.